Cell viability was evaluated by crystal violet assay, synergism was evaluated using the SynergyFinder 3.0 software, using previous data from the viability assay, cell death was determined using annexin V and PI assay and finally, metabolic responses in OCR in the canine oral melanoma cell line CMGD5 and human cutaneous melanoma SK-MEL-28 were performed to determine if the drugs were metabolically effective in these tumor types. The gene discussed is ANXA5; the disease is cutaneous melanoma.